Clareo Health | Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ottawa Hospital Research Institute
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with either radiologically and/or histologically confirmed bone metastases from castrate resistant prostate cancer or breast cancer who are currently receiving BMA
Patient has received BMA for 2 or more years counting from the first BMA dose for bone metastases
Age 18 years or older
Able to provide verbal consent
You may not be if
Definite contraindication for BMA
History of, or current evidence of osteonecrosis of the jaw
Radiotherapy or surgery to the bone planned within 4 weeks after randomization
Current hypercalcemia defined as corrected serum calcium of \> 3 mmol/L (from standard bloodwork completed within one month prior to treatment dose)
